ICMJE DISCLOSURE FORM

Date:2022.10	21
	Hong Jia
Manuscript Title:_	TGR5 overexpression mediated by the inhibition of transcription factor SOX9 protects against
hypoxia-/reoxyger	ation-induced injury in hippocampal neurons by activating Nrf2/HO-1
signaling	
Manuscript number	er (if known):
	ansparency, we ask you to disclose all relationships/activities/interests listed below that are ent of your manuscript. "Related" means any relation with for-profit or not-for-profit third
	rests may be affected by the content of the manuscript. Disclosure represents a commitment
•	d does not necessarily indicate a bias. If you are in doubt about whether to list a

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	X None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ X None	
3	Royalties or licenses	_ X None	
4	Consulting fees	_ X None	

5	Payment or honoraria for lectures, presentations,	_ X None		
	speakers bureaus,			
	manuscript writing or			
-	educational events			
6	Payment for expert	X None		
	testimony			
7	Consent for attending	Y N		
/	Support for attending meetings and/or travel	_ X None		
	meetings and/or traver			
8	Patents planned, issued or	X None		
0	pending	X None		
	perianig			
9	Participation on a Data	X None		
	Safety Monitoring Board or	_ XNone		
	Advisory Board			
10	Leadership or fiduciary role	X None		
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	X None		
12	Descipt of aguinment	V Name		
12	Receipt of equipment, materials, drugs, medical	X None		
	writing, gifts or other			
	services			
13	Other financial or non-	_ X None		
	financial interests			
Ple	Please summarize the above conflict of interest in the following box:			
	The author has no conflicts of interest to declare.			
Ple	ase place an "X" next to the	e following statement to in	dicate your agreement:	

__ X _ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Da	te:2022.10.21			
Yo	ur Name: Yaoqi Cher			_
			d by the inhibition of transcription factor SOX9 protects	s against
	• •	ed injury in hippocampal i	neurons by activating Nrf2/HO-1	
_				
Ma	anuscript number (if known))=		
rela pai to	ated to the content of your rties whose interests may be	manuscript. "Related" me e affected by the content on necessarily indicate a bias.	Il relationships/activities/interests listed below that are cans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment . If you are in doubt about whether to list a o so.	
	e following questions apply inuscript only.	to the author's relationsh	ips/activities/interests as they relate to the current	
to i me	the epidemiology of hypertoedication, even if that medic	ension, you should declare cation is not mentioned in pport for the work reporte	defined broadly. For example, if your manuscript perta e all relationships with manufacturers of antihypertensi the manuscript. ed in this manuscript without time limit. For all other it	ve
		Name all entities with	Specifications/Comments	
		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)	
		Time frame: Since the initia	l planning of the work	
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone		
		Time frame: pas	t 36 months	

Grants or contracts from

in item #1 above).

Royalties or licenses

Consulting fees

4

any entity (if not indicated

Χ_

X

X

_None

None

_None

5	Payment or honoraria for	X None		
5	lectures, presentations,	_ X None		
	speakers bureaus,			
	manuscript writing or educational events			
6	Payment for expert	_ X None		
	testimony			
-	C 15 11 12	Y		
7	Support for attending meetings and/or travel	_ X None		
8	Patents planned, issued or	_ X None		
	pending			
9	Participation on a Data	X None		
	Safety Monitoring Board or	XNone		
	Advisory Board			
10	Leadership or fiduciary role	_ X None		
	in other board, society, committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	X None		
	•			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other	X None		
	services			
13	Other financial or non- financial interests	_ X None		
Ple	ease summarize the above c	onflict of inter	rest in the following box:	
	The author has no conflicts of interest to declare.			
	The author has no conflicts of interest to declare.			

__ X _ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Please place an "X" next to the following statement to indicate your agreement:

ICMJE DISCLOSURE FORM

ICIVISE DISCLOSURE FORIVI
Date:2022.10.21
Your Name: Yalin Liu
Manuscript Title: TGR5 overexpression mediated by the inhibition of transcription factor SOX9 protects agains hypoxia-/reoxygenation-induced injury in hippocampal neurons by activating Nrf2/HO-1 signaling
Manuscript number (if known):
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.
The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.
The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive

medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items,

the time frame for disclosure is the past 36 months.

Name all entities with **Specifications/Comments** whom you have this (e.g., if payments were made to you or to your relationship or indicate institution) none (add rows as needed) Time frame: Since the initial planning of the work All support for the present Χ None manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Time frame: past 36 months Grants or contracts from **X** None any entity (if not indicated in item #1 above). Royalties or licenses X None 4 Consulting fees X None

		1	I
5	Payment or honoraria for	X None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	_ X None	
	testimony		
7	Cuppert for attending	V Name	
7	Support for attending meetings and/or travel	_ X None	
8	Patents planned, issued or	_ X None	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or	_ XNone	
	Advisory Board		
10	Leadership or fiduciary role	_ X None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	X None	
	Stock of Stock options	_ XNone	
12	Receipt of equipment,	_ X None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	X None	
13	financial interests	_ XNone	
	rase summarize the above case summarize the above cases. The author has no conflict		llowing box:
Dla	ase place an "X" next to the	e following statement to in	dicate vour agreement:

__ X _ I certify that I have answered every question and have not altered the wording of any of the questions on this

form.